The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Abstract
A total of 300 new bisphosphonates were screened for their effect on bone resorption in the rat. Among these, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was selected for detailed investigation. It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroid-ectomized rats at a SC dose as low as 0.001 mg P (0.016 μmol) per kg body weight per day. The compound was thus about 2, 10, 50, and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively. Intravenous administration was as effective as subcutaneous, and oral administration was 100 times less effective. The effect after one administration decreased with time but was still measurable after 2 weeks. Nonstimulated bone resorption assayed by the urinary excretion of radiolabeled tetracycline from lifelong prelabeled animals was also inhibited. This effect started 3 days after a single dose and was still maximal after 7 days. Histomorphometric analysis of the tibial metaphysis in growing intact rats also showed an inhibition of bone resorption along with an increase in bone mass. The number of osteoclasts increased in animals treated with 0.01 and 0.1 mg P per kg (0.16 and 1.6 μmol/kg) body weight SC but decreased in animals given 1 mg P per kg (16.1 μmol/kg), showing that the inhibition of bone resorption was not due to an inhibition of osteoclast recruitment. No inhibition of mineralization occurred. This new bisphosphonate appears to have great potential for use in human bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [141]
Citations
Cites
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Self-citationHandbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Self-citationThe Role of Phosphonates in Living Systems
Hilderbrand (2018) · CRC Press eBooks · doi:10.1201/9781351076470 · Cited by 544
Brown, W. A. B. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)81367-3 · Cited by 495
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Self-citationTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citation
Research works printed but not linked: 8
- Kanis, 1987, Clodronate – a new perspective in the treatment of neoplastic bone disease, Bone (Suppl.), 8, S1
- Burckhardt, 1989, Disodium Pamidronate (APD) in the Treatment of Malignancy-Related Disorders
- Charhon, 1986, Histomorphometric analysis of bone biopsies of baboons treated with “SR 41319BH,” a new diphosphonate (abstract), Calcif Tissue Int, 38, 124
- Bevan, 1988, Bisphosphonate action in the oophorectomized rat: The effects of 2-(3-pyridinyl)-1-hydroxyethylidene-bis(phosphonate) on skeletal metabolism; comparison with etidronate (abstract), J Bone Miner Res (Suppl.), 3, 498
- Valentin-Opran, 1990, Risedronate: Preliminary results of a pharmacologic study in pagetic patients. Twelfth Annual Meeting of the American Society for Bone and Mineral Research, Atlanta, Georgia, August 28–31, 1990 (abstract 182), J Bone Miner Res, 5
- Mühlbauer, 1990, A method for continual monitoring of bone resorption in the rat: Evidence for a diurnal rhythm, Am J Physiol, 259, R679
- Schenk, 1984, Methods of Calcified Tissue Preparation, 1
- Mühlbauer, 1989, 1-Hydroxy-3-(methylpentyl-amino)propylidene-bisphosphonate (BM 21.0955), a potent new inhibitor of bone resorption. Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Res, Montréal, Québec, Canada, September 9–14, 1989, J Bone Miner Res, 4
Cited by
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
“Ibandronate is a highly potent nitrogen-containing bisphosphonate((17)) that has the potential to be administered intermittently with extended between-dose intervals.”
BackgroundBisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Self-citationCellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Self-citation
Metadata
- Authors
- Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H.
- Affiliations
- University of Bern (CH)
- Boehringer Mannheim, Mannheim, Germany
- Corresponding author
- Mühlbauer, R.C.
- ORCID
- Janner, M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 1003-1011
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2012291531
- Cited by
- 239
- References
- 30
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, risedronate, alendronate, pamidronate, clodronate, bone mass, bone histomorphometry
- MeSH terms
- Risedronic Acid, Pamidronate, Ibandronic Acid, Animals, Benzoates, Bone Resorption, Calcium, Clodronic Acid, Diphosphonates, Injections, Intravenous, Osteoclasts, Retinoids, Etidronic Acid, Spectrophotometry, Atomic, Tetracycline, Thyroxine, Alendronate, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. https://app.cochat.ai/papers/10.1002/jbmr.5650060915
- The paper
- Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991). BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.5650060915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.